SCHEDULE: Cormorant Asset Management Discloses MoonLake Stake

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 4.35% in MoonLake Immunotherapeutics' Class A ordinary shares.

Summary

• Cormorant Asset Management, LP, acting as an investment adviser, and Bihua Chen have jointly filed a Schedule 13G, indicating their beneficial ownership of MoonLake Immunotherapeutics' Class A ordinary shares.
• The filing reports a total of 3,205,433 shares, representing 4.35% of the class.
• This ownership is held through Cormorant Funds, with shared voting and dispositive power attributed to both Cormorant Asset Management, LP and Bihua Chen.
• The filing is an amendment (Amendment No. 2) to a previous filing dated February 17, 2026.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but not controlling stake by an investment manager, with no immediate negative implications.

Positives

• Significant investment by a known asset manager (Cormorant Asset Management, LP) suggests confidence in the company's prospects.
• The stake, while substantial, is below the threshold that would typically trigger control concerns or require a more burdensome filing (e.g., Schedule 13D).
• The filing confirms the total number of outstanding shares as of May 1, 2026, based on the company's Q1 2026 10-Q filing.

Negatives

• No specific negative financial or operational information is presented in this Schedule 13G filing, as it is primarily an ownership disclosure.

Risks

• While not explicitly stated as a risk in this filing, a significant stake by an activist investor could potentially lead to future pressure on management or strategic changes.
• The filing does not provide details on the investment strategy or rationale behind acquiring this stake, leaving room for speculation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "The foregoing persons are hereinafter sometimes collectively referred to as the 'Reporting Persons.'"
• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Cormorant Asset Management's interest in MoonLake Immunotherapeutics, a biotechnology company, aligning with typical investment patterns in the sector.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest, potentially influencing share price, but also introduces a significant holder whose future actions could impact the stock.
• Management: The presence of a substantial shareholder may lead to increased scrutiny or engagement from Cormorant Asset Management, LP.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Continued monitoring of MoonLake Immunotherapeutics' performance and any further filings by Cormorant Asset Management, LP or Bihua Chen.
• Potential for future filings if ownership levels change significantly.

Key Dates

Recommendation

This filing is a disclosure of ownership and does not provide new operational or financial data. While Cormorant Asset Management's investment is noted, it does not offer sufficient information to warrant a buy or sell recommendation. A 'hold' is appropriate pending further company-specific developments or disclosures.

Keywords

MoonLake Immunotherapeutics, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, Investment Adviser, Shareholder Disclosure